AI Analysis Center: VSTM

Perform detailed analysis with custom AI prompts
Back to Symbol
Click to Interact
Open VSTM in TradingView
Stock Overview
5-minute deep dive through the eyes of Buffett & Lynch.
Generate Prompt
Earnings Preview
Expectations, scenarios, and price impact for upcoming earnings.
Generate Prompt
Red Flag Detector
Identify hidden risks and 'red flags' in the stock.
Generate Prompt
Valuation Story
Discover the fundamental story and multiple analysis behind the price.
Generate Prompt
Chart Analysis
Understand technical patterns and key levels in plain text.
Generate Prompt
Sentiment Tracker
Track news, social media, and analyst sentiment.
Generate Prompt
ETF Exposure
Discover which ETFs hold this stock and their allocation weight.
Generate Prompt
Portfolio Opt.
AI suggestions to improve your risk/return balance.
Generate Prompt
Strategy Matching
Find the strategies that best fit your personal risk profile.
Generate Prompt
What-If Backtest
Historic 'what if I invested this much' test with past data.
Generate Prompt
Position Sizing
Calculate the optimal buy amount for risk management.
Generate Prompt
Exit Strategy
Smart exit strategy with take-profit and stop-loss levels.
Generate Prompt
Tax-Loss Harvesting
Portfolio maneuvers for year-end tax savings.
Generate Prompt
Comparison & Peer
Multi-dimensional comparison with industry peers.
Generate Prompt
Peer Discovery
Discover other investment opportunities similar to your stock.
Generate Prompt
Catalyst Calendar
Key events in the next 90 days that could impact the price.
Generate Prompt
Sector Rotation
Which sector to rotate into in the current macro environment?
Generate Prompt
Smart Alerts
AI-powered commentary for price and volume movements.
Generate Prompt
Anomaly Detection
Suspicious and unusual movements in financial data.
Generate Prompt
Compliance Monitor
Regulatory compliance and legal risk analysis.
Generate Prompt
Volatility Forecast
Expected price fluctuations for the next 30 days.
Generate Prompt
Risk Scenarios
Stress test for situations like recession or rate hikes.
Generate Prompt
Insider Activity
Interpret the latest trading moves by executives.
Generate Prompt
AI Q&A (Evidence)
Answer your questions about the stock with official documents.
Generate Prompt
Due Diligence
Enterprise-grade data room and document analysis.
Generate Prompt
Dividend Safety
Check dividend sustainability and cut risk.
Generate Prompt
Options Strategy
Advanced options plans optimized for your outlook.
Generate Prompt
NOT INVESTMENT ADVICE: All AI outputs are for educational and informational purposes only. Final decisions are your own responsibility.
Scalp Analysis
1-15 Min
Real-time scalp opportunities: entry/exit points, risk levels for 1-15 minute trades.
Generate Prompt
Swing Analysis
2-10 Days
2-10 day swing trade setups: trend analysis, position management strategy.
Generate Prompt
Hold / Investment Analysis
3-12+ Mo
3-12+ month investment thesis: valuation, growth catalysts, portfolio allocation.
Generate Prompt
Affiliate links — DocuRefinery may earn a commission when you open an account.

Interactive Brokers

SEC, FINRA, FCA, ASIC Regulation $0 Min. Deposit
Access 150+ global markets. Stocks, ETFs, Options, Futures, Forex.
Open Account

TD Ameritrade (Schwab)

SEC, FINRA Regulation $0 Min. Deposit
Industry-leading trading platforms and comprehensive education.
Open Account
All investing involves risk, including the possible loss of principal. Past performance does not guarantee future results.

Latest News — VSTM

Verastem, Inc. — Company Profile & Analysis

Verastem, Inc., founded in 2010 and headquartered in Needham, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative, small-molecule drugs aimed at treating high-unmet-need cancers. Since its inception, the company has focused on the complex biology of the RAS/MAPK signaling pathway, a critical driver in numerous oncology indications. Verastem’s mission is to transform the lives of patients by addressing the compensatory mechanisms that allow cancer cells to survive and proliferate despite traditional therapeutic interventions, positioning itself as a specialized player in the precision oncology landscape.

The company’s primary product pipeline centers on two key assets: Avutometinib and Defactinib. Avutometinib is a potent, orally administered dual RAF/MEK inhibitor designed to block MEK kinase activity and prevent the compensatory reactivation of MEK by upstream RAF. When combined with Defactinib, an oral small-molecule inhibitor of FAK (focal adhesion kinase) and proline-rich tyrosine kinase, the company aims to provide a synergistic therapeutic effect. This combination is currently being evaluated in several high-profile clinical trials, including RAMP 201 and RAMP 301, which focus on recurrent low-grade serous ovarian cancer, as well as the RAMP 203 trial, which explores the combination of Avutometinib with Amgen’s LUMAKRAS for KRAS-G12C mutant cancers.

Verastem occupies a strategic niche in the biopharmaceutical market by leveraging a robust network of global collaborations. By maintaining license agreements with industry giants such as Chugai Pharmaceutical and Pfizer, as well as clinical collaborations with Amgen and GenFleet Therapeutics, the company effectively de-risks its development programs while expanding its reach into diverse patient demographics. Its target demographic includes patients with solid tumors driven by RAS pathway mutations, a significant and difficult-to-treat segment of the oncology market. The company’s focus on 'co-pack' therapeutic strategies, such as AVMAPKI and FAKZYNJA, reflects a commitment to integrated treatment regimens that address the biological complexity of cancer.

Looking toward the future, Verastem is strategically positioned to advance its lead programs through late-stage clinical development and potential regulatory filings. The company’s focus on the RAMP (RAF/MEK/FAK) platform represents a long-term commitment to establishing a new standard of care for patients with RAS-driven malignancies. By continuously refining its pipeline and fostering discovery-stage partnerships, such as the collaboration with GenFleet, Verastem aims to sustain its growth trajectory. The company’s ability to navigate the regulatory environment while maintaining a lean, research-focused operational model will be critical as it transitions from a development-stage entity toward potential commercialization.

Economic Moat Verastem’s competitive advantage lies in its specialized focus on the RAS/MAPK signaling pathway and its proprietary combination therapy platform, which addresses the critical issue of compensatory resistance in cancer cells. By securing strategic intellectual property and high-value clinical collaborations with major pharmaceutical entities like Pfizer and Amgen, the company creates significant barriers to entry for competitors attempting to replicate its synergistic RAF/MEK/FAK inhibitor approach.
CEO Mr. Daniel W. Paterson
Employees 102
Headquarters United States
Market Competitors
CLVS CRSP EDIT BLUE GTHX
Smart Tags
#VSTM #Biotech #Oncology #NASDAQ #PrecisionMedicine #CancerResearch #ClinicalTrials

Market Insights & Investor Q&A — VSTM

Frequently Asked Questions

How can I use AI-powered ready-made templates to analyze the VSTM stock?
On the DocuRefinery platform you will find a no‑signup, free template that works with verified data for VSTM. Just enter the ticker, select risk analysis or dividend yield options, and the AI generates a detailed report in seconds.
What prompt should I use to get a hallucination‑free dividend yield analysis for VSTM?
Choose the ready-made prompt that includes "dividend yield" and "verified data" filters. The AI scans VSTM's historical payouts, applies a calibrated model, and returns an accurate yield estimate without any AI hallucinations.
Can I perform a portfolio stress test for VSTM using a free AI tool?
DocuRefinery offers an instant, no‑registration stress‑test template. Add VSTM to your portfolio, set the market scenarios, and the AI instantly runs a risk simulation, delivering a clear, actionable report.

Deep Analysis

AI‑Enabled Ready Solutions for VSTM Investment Analysis

When evaluating a single ticker like VSTM, AI methodologies such as risk modeling, trend detection, and balance‑sheet scanning provide a clear edge over traditional spreadsheet work. While manual analysis can take hours, AI‑driven ready prompts deliver comprehensive insights in moments.

DocuRefinery lets investors leverage its instant, free, no‑signup templates to run deep dives on VSTM. A single command pulls verified data, runs AI simulations across multiple scenarios, and presents the results in an easy‑to‑read format.

The advantage of an AI approach lies in its ability to produce hallucination‑free, data‑driven outcomes quickly. Using ready-made prompts, you can monitor VSTM's volatility profile, dividend yield, and market sensitivity with just a few clicks.

Through prompt engineering, users can tailor their analysis to specific strategies. For example, combine VSTM's historical performance with verified data filters to build a custom forecast model, then execute it instantly on DocuRefinery for fast, reliable decision support.